Medulloblastomics: The end of the beginning

Paul A. Northcott, David T.W. Jones, Marcel Kool, Giles W. Robinson, Richard J. Gilbertson, Yoon Jae Cho, Scott L. Pomeroy, Andrey Korshunov, Peter Lichter, Michael D. Taylor, Stefan M. Pfister

Research output: Contribution to journalReview articlepeer-review

388 Scopus citations

Abstract

The division of medulloblastoma into different subgroups by microarray expression profiling has dramatically changed our perspective of this malignant childhood brain tumour. Now, the availability of next-generation sequencing and complementary high-density genomic technologies has unmasked novel driver mutations in each medulloblastoma subgroup. The implications of these findings for the management of patients are readily apparent, pinpointing previously unappreciated diagnostic and therapeutic targets. In this Review, we summarize the 'explosion' of data emerging from the application of modern genomics to medulloblastoma, and in particular the recurrent targets of mutation in medulloblastoma subgroups. These data are currently making their way into clinical trials as we seek to integrate conventional and molecularly targeted therapies.

Original languageEnglish (US)
Pages (from-to)818-834
Number of pages17
JournalNature Reviews Cancer
Volume12
Issue number12
DOIs
StatePublished - Dec 2012

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Medulloblastomics: The end of the beginning'. Together they form a unique fingerprint.

Cite this